XEMPERIA

Share this actor

Xemperia ia a spin-off start-up company of the University of Fribourg, Switzerland, established in 2023, based on over 25 years of experience in groundbreaking translational cancer research and biomarker discovery.
Xemperia is dedicated to advancing innovation in the field of blood tests for cancer detection, monitoring and therapeutic decisions by leveraging the systemic body responses to cancer to identify cancer-associated biomarkers through a multiomic approach.
The aim is to reduce cancer mortality and enhancing patients’ quality of life by identifying and addressing cancer at its earliest and most treatable stages. The company develops accurate, easy and affordable molecular tests and nanosensors that seamlessly integrate into contemporary medical practices.